Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
615 stopped studies mapped to Melanoma and descendants · 90% state a reason
Over the 615 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03370861 | How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes(MINING) | — | terminated | Dec 12, 2017 | Washington University School of Medicine | Subject recruitment was limited severely by the 2020-2023 COVID-19 pandemic, which led this study… | COVID-19 / pandemic |
| NCT04768881 | Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced… | Phase 2 | terminated | Feb 24, 2021 | Karyopharm Therapeutics Inc | The trial was terminated due to a lack of sufficient anti-melanoma tumor signal for the combination… | Other (stated, no rule matched) |
| NCT02535078 | Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in… | Phase 1 / Phase 2 | withdrawn | Aug 28, 2015 | Immunocore Ltd | not stated | Not stated |
| NCT03233828 | Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2(IL-2) | Phase 3 | terminated | Jul 31, 2017 | Carman Giacomantonio | Low enrollment numbers. | Enrollment / accrual |
| NCT03978611 | A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced… | Phase 1 | terminated | Jun 7, 2019 | Bristol-Myers Squibb | Business objectives have changed. | Sponsor / business decision |
| NCT04198818 | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient… | Phase 1 / Phase 2 | terminated | Dec 13, 2019 | Haihe Biopharma Co., Ltd. | Sponsor business decision | Sponsor / business decision |
| NCT04924413 | L-TIL Plus Tislelizumab as First-line Treatment in Advanced Malignant Melanoma | Phase 2 | terminated | Jun 14, 2021 | Quanli Gao | Slow enrollment | Enrollment / accrual |
| NCT03685591 | PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors | Phase 1 | terminated | Sep 26, 2018 | Pfizer | The decision to stop enrollment was due to strategic considerations and not due to any specific… | Safety / toxicity |
| NCT05545969 | Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma(Neo PeLeMM) | Phase 2 | withdrawn | Sep 19, 2022 | Melanoma Institute Australia | Insufficient funding | Funding |
| NCT03621982 | Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2018 | ADC Therapeutics S.A. | Cami in combination with pembrolizumab in solid tumors showed signals of immunomodulatory activity.… | Other (stated, no rule matched) |
| NCT04655157 | Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With…(QUAD01) | Phase 1 / Phase 2 | terminated | Dec 7, 2020 | Jason J. Luke, MD | Study terminated due to slow enrollment | Enrollment / accrual |
| NCT03893019 | MB-CART20.1 Melanoma | Early Phase 1 | terminated | Mar 27, 2019 | Miltenyi Biomedicine GmbH | The risk-benefit assessment was not as expected. | Other (stated, no rule matched) |
| NCT02621515 | Nivo/Ipi Combination Therapy in Symptomatic Brain Metastases(CA209-322) | Phase 2 | terminated | Dec 3, 2015 | University Medical Center Groningen | In the Netherlands we wanted to add pilimumab to nivolumab. This resulted in a very long METC… | Other (stated, no rule matched) |
| NCT02700763 | [18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis | N/A | terminated | Mar 7, 2016 | University Medical Center Groningen | Due to the very low inlcusion rate and the current COVID-19 pandemic. | COVID-19 / pandemic |
| NCT02922283 | IL2 Imaging in Metastatic Melanoma | N/A | terminated | Oct 4, 2016 | University Medical Center Groningen | After an interim analysis of the data, it became clear that the imaging results did not correlate… | Efficacy / futility |
| NCT00199342 | A Study of a Monoclonal Antibody, KW-2871, in Patients With Advanced Melanoma | Phase 1 / Phase 2 | terminated | Sep 20, 2005 | Kyowa Kirin, Inc. | Occurrence of 2 dose-limiting toxicities at the initial dose level (60 mg/m2) in Part I. | Safety / toxicity |
| NCT04879017 | FHD-286 in Subjects With Metastatic Uveal Melanoma | Phase 1 | terminated | May 10, 2021 | Foghorn Therapeutics Inc. | Sponsor terminated the study for business reasons. | Sponsor / business decision |
| NCT05709821 | IMM60 and Pembrolizumab in Melanoma and NSCLC | Phase 1 / Phase 2 | terminated | Feb 2, 2023 | iOx Therapeutics | Prioritization of other pipeline assets. No safety or efficacy issues were observed. | Safety / toxicity |
| NCT05050006 | ITIL-168 in Advanced Melanoma(DELTA-1) | Phase 2 | terminated | Sep 20, 2021 | Instil Bio | Business Decision | Sponsor / business decision |
| NCT05061537 | Study of PF-07263689 in Participants With Selected Advanced Solid Tumors | Phase 1 | terminated | Sep 29, 2021 | Pfizer | The study was terminated by the Sponsor due to business decision and not due to any safety concerns… | Safety / toxicity |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | Phase 1 | suspended | Jan 20, 2021 | DNAtrix, Inc. | DNAtrix management decision not based on study design, safety, or site performance. | Safety / toxicity |
| NCT02978443 | A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab… | Phase 2 | terminated | Dec 1, 2016 | Georgetown University | Lack of Enrollment | Enrollment / accrual |
| NCT03727789 | CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma | Phase 1 | terminated | Nov 1, 2018 | Roswell Park Cancer Institute | low accrual | Enrollment / accrual |
| NCT03932253 | MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant… | Phase 1 | suspended | Apr 30, 2019 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Sponsor R\&D strategy adjustment | Sponsor / business decision |
| NCT04899921 | Troriluzole or Placebo Plus Ipi Plus Nivo in Mel Brain Mets | Phase 2 | terminated | May 25, 2021 | Dana-Farber Cancer Institute | Due to poor enrollment | Enrollment / accrual |
| NCT02723006 | Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational… | Phase 1 | terminated | Mar 30, 2016 | Millennium Pharmaceuticals, Inc. | Business decision: Protocol efficacy futility met | Efficacy / futility |
| NCT00003552 | Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With… | Phase 1 / Phase 2 | terminated | Mar 5, 2007 | National Heart, Lung, and Blood Institute (NHLBI) | not stated | Not stated |
| NCT04455503 | Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 | Phase 1 / Phase 2 | terminated | Jul 2, 2020 | Evaxion Biotech A/S | Based on the promising interim results of study part 1, it was decided to further accelerate the… | Enrollment / accrual |
| NCT05060003 | Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma… | Phase 2 | terminated | Sep 28, 2021 | Washington University School of Medicine | Sponsor made decision to terminate study. | Other (stated, no rule matched) |
| NCT04337931 | A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic… | Phase 2 | terminated | Apr 8, 2020 | Apexigen America, Inc. | Business decision (not due to safety reason). | Safety / toxicity |
| NCT05756556 | T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma | Phase 2 | suspended | Mar 6, 2023 | ImmVira Pharma Co. Ltd | Change in drug development and lifecycle management and decide to suspend this study | Other (stated, no rule matched) |
| NCT04242329 | Surgery of Melanoma Metastases After Systemic Therapy(SUMMIST) | Phase 2 | withdrawn | Jan 27, 2020 | Vastra Gotaland Region | Not possible to recruit patients during COVID, and not possible to start enrolling after the… | COVID-19 / pandemic |
| NCT01769222 | Ipilimumab and Local Radiation for Selected Solid Tumors | Phase 1 | terminated | Jan 16, 2013 | Stanford University | Planned Future Study | Other (stated, no rule matched) |
| NCT05482074 | Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 | Phase 2 | withdrawn | Aug 1, 2022 | Dana-Farber Cancer Institute | Principal Investigator left the institute | Investigator |
| NCT03709771 | Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint… | — | terminated | Oct 17, 2018 | Vanderbilt University Medical Center | Study terminated due to unmet targeted accrual goals with only 2 subjects accrued out of 80 planned… | COVID-19 / pandemic |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT00979693 | Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma | Phase 2 | withdrawn | Sep 18, 2009 | Multidisciplinary Association for Psychedelic Studies | The study was suspended because the PI was unable to get permission from his department to submit… | Other (stated, no rule matched) |
| NCT04809805 | A Study to Learn How Safe BAY2666605 is, How it Affects the Body, How it Moves Into,… | Phase 1 | terminated | Mar 22, 2021 | Bayer | Due to the high probability of not achieving a therapeutic window and lack of evidence of… | Other (stated, no rule matched) |
| NCT04663126 | Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma(Tilmanocept) | Early Phase 1 | terminated | Dec 10, 2020 | John O. Prior | after inclusion of 5 patients, tracer had low uptake (kidney/liver) | Other (stated, no rule matched) |
| NCT02382549 | A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and…(Mel61) | Early Phase 1 | terminated | Mar 6, 2015 | Craig L Slingluff, Jr | The study was terminated because of slow accruals. | Enrollment / accrual |
| NCT01856023 | HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma(PROCLIVITY02) | Phase 4 | terminated | May 17, 2013 | Clinigen, Inc. | slow accrual \& early closure | Enrollment / accrual |
| NCT04894994 | FLX475 in Combination With Ipilimumab in Advanced Melanoma | Phase 2 | terminated | May 20, 2021 | RAPT Therapeutics, Inc. | Change in clinical landscape | Other (stated, no rule matched) |
| NCT04589832 | Study of PAC-1 and Entrectinib for Patients With Metastatic Uveal Melanoma | Phase 1 / Phase 2 | terminated | Oct 19, 2020 | Arkadiusz Z. Dudek, MD | This study required dose reductions to the lower dose level (Dose level -1). But this dose level… | Funding |
| NCT04785365 | Long-Term Follow-Up Study of Patients Receiving ATL001 | Phase 2 | terminated | Mar 5, 2021 | Achilles Therapeutics UK Limited | The long-term follow-up of patients is being migrated to the original (parent) study protocols… | Other (stated, no rule matched) |
| NCT02143050 | Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients | Phase 1 / Phase 2 | withdrawn | May 20, 2014 | University of Louisville | No participant enrollment | Enrollment / accrual |
| NCT02425306 | Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of…(Mel63; CHAMP) | Phase 1 / Phase 2 | terminated | Apr 23, 2015 | Craig L Slingluff, Jr | Slow accrual to part 2 of the study. Accrual to part 1 is complete. | Enrollment / accrual |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With… | Phase 1 / Phase 2 | withdrawn | Oct 19, 2023 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT02743611 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or… | Phase 1 / Phase 2 | terminated | Apr 19, 2016 | Bellicum Pharmaceuticals | company decision | Sponsor / business decision |
| NCT03272464 | INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant… | Phase 1 | terminated | Sep 5, 2017 | Massachusetts General Hospital | Slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Sep 5, 2024source: clinicaltrials